SCHEMBL29214974

SCHEMBL29214974

CCOc1ccc(-c2cncc(C(=O)NN=Cc3ccccc3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.61
▸ SCN2A Q99250 3/20 0.60
▸ SCN10A Q9Y5Y9 3/20 0.60
▸ MAPT P10636 5/20 0.53
▸ MAPK1 P28482 2/20 0.53
▸ LMNA P02545 2/20 0.53
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ MEN1 O00255 4/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ NPC1 O15118 2/20 0.53
▸ POLB P06746 1/20 0.53
▸ IDO1 P14902 1/20 0.52
▸ KDM4E B2RXH2 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ GAA P10253 1/20 0.50
▸ XBP1 P17861 1/20 0.50
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30925977 1.00 RAB9A (0.61) RAB9ASCN2ASCN10AMAPTMAPK1
SCHEMBL24994288 1.00 RAB9A (0.61) RAB9ASCN2ASCN10AMAPTMAPK1
SCHEMBL29214849 0.92 SCN2A (0.58) RAB9ASCN2ASCN10AMAPTSMN1; SMN2
SCHEMBL24993515 0.92 SCN2A (0.58) RAB9ASCN2ASCN10AMAPTSMN1; SMN2
SCHEMBL24993519 0.91 KMT2A (0.57) RAB9ASCN2ASCN10AMAPTLMNA
SCHEMBL29214944 0.91 KMT2A (0.57) RAB9ASCN2ASCN10AMAPTLMNA
SCHEMBL24993513 0.88 ALDH1A1 (0.57) RAB9ASCN2ASCN10AMAPTMAPK1
SCHEMBL30925901 0.88 ALDH1A1 (0.57) RAB9ASCN2ASCN10AMAPTMAPK1
SCHEMBL29214942 0.88 ALDH1A1 (0.57) RAB9ASCN2ASCN10AMAPTMAPK1
SCHEMBL30925942 0.88 ALDH1A1 (0.63) SCN2ASCN10AMAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) 2024-10-10 — — US claimed
CN-118076348-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN claimed
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) 2024-10-10 — — US disclosed
CN-118076348-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS SCN1A, SCN7A, SCN8A RAB9A 1530/4885SCN2A 6/4885SCN10A 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback